Physician profile
Anthony Cipolla
NPI 1063417327
$2,788.31
in general payments reported to CMS, 2019-2025
20 companies · $1,093 in 2025
The $1,093 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $895 · 2020: $118 · 2022: $48.98 · 2023: $184 · 2024: $448 · 2025: $1,093.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,726.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,725.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $479.18 | 2023-2025 | |
| Amarin Pharma, INC. | $474.71 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $357.69 | 2020-2025 | Jardiance |
| Novo Nordisk INC | $245.28 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $241.66 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Merck Sharp & Dohme LLC | $162.59 | 2019-2025 | Verquvo, Capvaxive, Gardasil 9 |
| Astrazeneca Pharmaceuticals Lp | $152.64 | 2019-2024 | Airsupra |
| Pfizer INC. | $145.09 | 2023-2025 | |
| Abbvie INC. | $80.87 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $68.15 | 2025 | Eliquis, Camzyos |
| Exact Sciences Corporation | $63.71 | 2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $61.12 | 2023-2025 | Trelegy Ellipta, Arexvy |
| Recordati_rare_diseases_inc. | $55.01 | 2025 | Isturisa |
| Janssen Biotech, INC. | $43.41 | 2022-2024 | Tremfya, Stelara, Simponi Aria |
| Amgen INC. | $43.18 | 2025 | Otezla, Repatha |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $32.23 | 2022 | |
| Abbott Laboratories | $26.03 | 2025 | Freestyle Libre 3 |
| Harmony Biosciences LLC | $25.46 | 2025 | |
| Esperion Therapeutics, INC. | $16.57 | 2024 | Nexletol |
| Dynavax Technologies Corporation | $13.73 | 2025 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Cipolla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.